Clinical Trial Update: An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients [Phase 2]

View source ↗

Summary

Phase 2 open-label trial evaluating a novel renal multivitamin in end-stage renal disease patients to assess effects on inflammation and related biomarkers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Novel renal multivitamin

Snippet

Sponsor: Nephrian | Conditions: Hyperphosphatemia, Inflammation | Phase 2 | Status: UNKNOWN